Document -

Glionova receives SEK 5 million grant from Swedish innovation agency VINNOVA

Stockholm 20 november, 2014 - Glionova Therapeutics has been granted SEK 4.95 million from Swedish innovation agency Vinnova, to conduct the pre-clinical development of GLN-1001, a novel agent for the potential treatment of glioblastoma, the most common and aggressive form of brain cancer.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.pdf
Download
Enter your email address to follow Glionova AB

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Glionova AB.

Okay